Chen R-C, Cai Y-J, Wu J-M, Wang X-D, Song M, Wang Y-Q, Zheng M-H, Chen Y-P, Lin Z, Shi K Q
Department of Liver Diseases, Liver Research Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Institute of Genomic Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
J Viral Hepat. 2017 Mar;24(3):238-245. doi: 10.1111/jvh.12638. Epub 2016 Nov 14.
Long-term prognosis varies widely among patients with hepatitis B virus (HBV)-related liver cirrhosis. Our study aimed to investigate the applicability of albumin-bilirubin (ALBI), Child-Pugh and model for end-stage liver disease (MELD) scores to the long-term prognosis prediction of HBV-related cirrhosis. Patients diagnosed with HBV-associated cirrhosis from the First Affiliated Hospital of Wenzhou Medical University between January 2010 and December 2015 were enrolled in this study. The patients were followed up every 3 months. The prognostic performance of ALBI in long-term outcome prediction for HBV-related cirrhosis was compared with Child-Pugh and MELD scores using time-dependent receiver operating characteristic curve (tdROC) and decision curve analysis. A total of 806 patients were included in our study with 275 (34.1%) deceased during the follow-up. Multivariate Cox regression analysis showed that ALBI grade was an independent predictor associated with mortality. The tdROC analysis showed that ALBI score (0.787, 0.830 and 0.833) was superior to MELD (0.693, P=.003; 0.717, P<.001; 0.744, P<.001) and Child-Pugh score (0.641, P<.001; 0.649, P<.001; 0.657, P<.001) for predicting 1-year, 2-year and 3-year mortality. Additionally, decision curves also got the similar results. In addition, patients with lower ALBI score had a longer life expectancy, even among patients within the same Child-Pugh class. Thus, ALBI score was effective in predicting the long-term prognosis for patients with HBV-related cirrhosis and more accurate than Child-Pugh and MELD scores.
乙肝病毒(HBV)相关肝硬化患者的长期预后差异很大。我们的研究旨在探讨血清白蛋白-胆红素(ALBI)分级、Child-Pugh评分和终末期肝病模型(MELD)评分在预测HBV相关肝硬化长期预后方面的适用性。本研究纳入了2010年1月至2015年12月期间在温州医科大学附属第一医院被诊断为HBV相关肝硬化的患者。对患者每3个月进行一次随访。使用时间依赖性受试者工作特征曲线(tdROC)和决策曲线分析,将ALBI分级在预测HBV相关肝硬化长期预后方面的性能与Child-Pugh评分和MELD评分进行比较。我们的研究共纳入806例患者,其中275例(34.1%)在随访期间死亡。多因素Cox回归分析显示,ALBI分级是与死亡率相关的独立预测因素。tdROC分析显示,在预测1年、2年和3年死亡率方面,ALBI评分(0.787、0.830和0.833)优于MELD评分(0.693,P = 0.003;0.717,P < 0.001;0.744,P < 0.001)和Child-Pugh评分(0.641,P < 0.001;0.649,P < 0.001;0.657,P < 0.001)。此外,决策曲线也得到了类似的结果。此外,即使在同一Child-Pugh分级的患者中,ALBI评分较低的患者预期寿命更长。因此,ALBI评分在预测HBV相关肝硬化患者的长期预后方面是有效的,并且比Child-Pugh评分和MELD评分更准确。